BMRN
BioMarin Pharmaceutical Inc.
BMRN
(2.8)63,42 USD
3.88% ROA
5.08% ROE
50.89x PER
13.077.408.270,00 USD
20.8% DER
0% Yield
9.91% NPM
BioMarin Pharmaceutical Inc. Stock Analysis
BioMarin Pharmaceutical Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
PBV
The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors. |
|
| 2 |
DER
The stock has a low debt to equity ratio (22%), which means it has a small amount of debt compared to the ownership it holds |
|
| 3 |
Assets Growth
Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity. |
|
| 4 |
ROE
The stock's ROE falls within an average range (3.3%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity. |
|
| 5 |
ROA
The stock's ROA (0.65%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits. |
|
| 6 |
Revenue Growth
Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice. |
|
| 7 |
Net Profit Growth
Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect. |
|
| 8 |
Graham Number
Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice. |
|
| 9 |
Dividend Growth
Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns. |
|
| 10 |
Dividend
The company's lack of dividends in the past three years may concern investors seeking regular income. |
|
| 11 |
Buffet Intrinsic Value
Warren Buffett's formula suggests that the company's stock is overpriced (-11.800), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value. |
BioMarin Pharmaceutical Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Buy |
| 2 | MACD | Buy |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Hold |
BioMarin Pharmaceutical Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 1998 | 1.200.000 | |
| 1999 | 6.976.000 | 82.8% |
| 2000 | 12.326.000 | 43.4% |
| 2001 | 11.699.000 | -5.36% |
| 2002 | 13.919.000 | 15.95% |
| 2003 | 12.100.000 | -15.03% |
| 2004 | 18.641.000 | 35.09% |
| 2005 | 25.669.000 | 27.38% |
| 2006 | 84.209.000 | 69.52% |
| 2007 | 121.581.000 | 30.74% |
| 2008 | 296.493.000 | 58.99% |
| 2009 | 324.656.000 | 8.67% |
| 2010 | 376.267.000 | 13.72% |
| 2011 | 441.358.000 | 14.75% |
| 2012 | 500.723.000 | 11.86% |
| 2013 | 548.485.000 | 8.71% |
| 2014 | 751.040.000 | 26.97% |
| 2015 | 889.895.000 | 15.6% |
| 2016 | 1.116.854.000 | 20.32% |
| 2017 | 1.313.646.000 | 14.98% |
| 2018 | 1.491.212.000 | 11.91% |
| 2019 | 1.704.048.000 | 12.49% |
| 2020 | 1.860.455.000 | 8.41% |
| 2021 | 1.846.275.000 | -0.77% |
| 2022 | 2.096.039.000 | 11.92% |
| 2023 | 2.325.316.000 | 9.86% |
| 2023 | 2.419.226.000 | 3.88% |
| 2024 | 2.834.632.000 | 14.65% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 1998 | 10.500.000 | |
| 1999 | 27.206.000 | 61.41% |
| 2000 | 35.794.000 | 23.99% |
| 2001 | 45.283.000 | 20.95% |
| 2002 | 54.455.000 | 16.84% |
| 2003 | 54.814.000 | 0.65% |
| 2004 | 49.784.000 | -10.1% |
| 2005 | 56.391.000 | 11.72% |
| 2006 | 66.735.000 | 15.5% |
| 2007 | 78.600.000 | 15.1% |
| 2008 | 93.291.000 | 15.75% |
| 2009 | 115.116.000 | 18.96% |
| 2010 | 147.309.000 | 21.85% |
| 2011 | 214.374.000 | 31.28% |
| 2012 | 302.218.000 | 29.07% |
| 2013 | 354.780.000 | 14.82% |
| 2014 | 461.543.000 | 23.13% |
| 2015 | 634.806.000 | 27.29% |
| 2016 | 661.905.000 | 4.09% |
| 2017 | 610.753.000 | -8.38% |
| 2018 | 696.328.000 | 12.29% |
| 2019 | 715.007.000 | 2.61% |
| 2020 | 628.116.000 | -13.83% |
| 2021 | 628.793.000 | 0.11% |
| 2022 | 649.606.000 | 3.2% |
| 2023 | 765.256.000 | 15.11% |
| 2023 | 746.773.000 | -2.48% |
| 2024 | 735.148.000 | -1.58% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 1998 | 3.500.000 | |
| 1999 | 6.805.000 | 48.57% |
| 2000 | 8.814.000 | 22.79% |
| 2001 | 6.718.000 | -31.2% |
| 2002 | 17.541.000 | 61.7% |
| 2003 | 14.396.000 | -21.85% |
| 2004 | 37.606.000 | 61.72% |
| 2005 | 41.556.000 | 9.51% |
| 2006 | 49.030.000 | 15.24% |
| 2007 | 77.539.000 | 36.77% |
| 2008 | 106.566.000 | 27.24% |
| 2009 | 124.290.000 | 14.26% |
| 2010 | 151.723.000 | 18.08% |
| 2011 | 175.423.000 | 13.51% |
| 2012 | 198.173.000 | 11.48% |
| 2013 | 235.356.000 | 15.8% |
| 2014 | 302.156.000 | 22.11% |
| 2015 | 402.271.000 | 24.89% |
| 2016 | 476.593.000 | 15.59% |
| 2017 | 554.336.000 | 14.02% |
| 2018 | 604.353.000 | 8.28% |
| 2019 | 0 | 0% |
| 2020 | 334.300.000 | 100% |
| 2021 | 354.300.000 | 5.64% |
| 2022 | 403.709.000 | 12.24% |
| 2023 | 408.400.000 | 1.15% |
| 2023 | 448.900.000 | 9.02% |
| 2024 | 560.928.000 | 19.97% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 1998 | -12.700.000 | |
| 1999 | -19.268.000 | 34.09% |
| 2000 | -18.333.000 | -5.1% |
| 2001 | -21.651.000 | 15.32% |
| 2002 | -38.350.000 | 43.54% |
| 2003 | -47.668.000 | 19.55% |
| 2004 | -34.929.000 | -36.47% |
| 2005 | -54.138.000 | 35.48% |
| 2006 | -12.715.000 | -325.78% |
| 2007 | -52.917.000 | 75.97% |
| 2008 | 54.189.000 | 197.65% |
| 2009 | 21.833.000 | -148.2% |
| 2010 | 8.071.000 | -170.51% |
| 2011 | -31.954.000 | 125.26% |
| 2012 | -91.922.000 | 65.24% |
| 2013 | -118.792.000 | 22.62% |
| 2014 | -137.758.000 | 13.77% |
| 2015 | -287.278.000 | 52.05% |
| 2016 | -192.433.000 | -49.29% |
| 2017 | -71.697.000 | -168.4% |
| 2018 | -100.250.000 | 28.48% |
| 2019 | -22.243.000 | -350.7% |
| 2020 | -5.850.000 | -280.22% |
| 2021 | 48.026.000 | 112.18% |
| 2022 | 159.515.000 | 69.89% |
| 2023 | 284.532.000 | 43.94% |
| 2023 | 261.983.000 | -8.61% |
| 2024 | 519.688.000 | 49.59% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 1998 | 1.900.000 | |
| 1999 | 13.070.000 | 85.46% |
| 2000 | 18.940.000 | 30.99% |
| 2001 | 11.699.000 | -61.89% |
| 2002 | 13.919.000 | 15.95% |
| 2003 | 12.100.000 | -15.03% |
| 2004 | 14.688.000 | 17.62% |
| 2005 | 23.040.000 | 36.25% |
| 2006 | 75.469.000 | 69.47% |
| 2007 | 103.222.000 | 26.89% |
| 2008 | 243.984.000 | 57.69% |
| 2009 | 258.747.000 | 5.71% |
| 2010 | 305.982.000 | 15.44% |
| 2011 | 357.335.000 | 14.37% |
| 2012 | 408.893.000 | 12.61% |
| 2013 | 452.743.000 | 9.69% |
| 2014 | 621.276.000 | 27.13% |
| 2015 | 737.887.000 | 15.8% |
| 2016 | 907.234.000 | 18.67% |
| 2017 | 1.071.860.000 | 15.36% |
| 2018 | 1.175.948.000 | 8.85% |
| 2019 | 1.344.582.000 | 12.54% |
| 2020 | 1.336.183.000 | -0.63% |
| 2021 | 1.375.760.000 | 2.88% |
| 2022 | 1.612.370.000 | 14.67% |
| 2023 | 1.826.336.000 | 11.72% |
| 2023 | 1.842.161.000 | 0.86% |
| 2024 | 2.255.600.000 | 18.33% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 1998 | -12.300.000 | |
| 1999 | -28.072.000 | 56.18% |
| 2000 | -37.364.000 | 24.87% |
| 2001 | -67.606.000 | 44.73% |
| 2002 | -77.461.000 | 12.72% |
| 2003 | -75.798.000 | -2.19% |
| 2004 | -187.443.000 | 59.56% |
| 2005 | -74.270.000 | -152.38% |
| 2006 | -28.533.000 | -160.3% |
| 2007 | -15.803.000 | -80.55% |
| 2008 | 30.831.000 | 151.26% |
| 2009 | -488.000 | 6417.83% |
| 2010 | 205.819.000 | 100.24% |
| 2011 | -53.836.000 | 482.31% |
| 2012 | -114.347.000 | 52.92% |
| 2013 | -176.353.000 | 35.16% |
| 2014 | -133.969.000 | -31.64% |
| 2015 | -171.799.000 | 22.02% |
| 2016 | -630.210.000 | 72.74% |
| 2017 | -117.042.000 | -438.45% |
| 2018 | -77.211.000 | -51.59% |
| 2019 | -23.848.000 | -223.76% |
| 2020 | 854.029.000 | 102.79% |
| 2021 | -64.080.000 | 1432.75% |
| 2022 | 141.561.000 | 145.27% |
| 2023 | 161.512.000 | 12.35% |
| 2023 | 167.645.000 | 3.66% |
| 2024 | 428.696.000 | 60.89% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 1998 | -1 | |
| 1999 | -1 | 0% |
| 2000 | -1 | 100% |
| 2001 | -2 | 0% |
| 2002 | -1 | 0% |
| 2003 | -1 | 0% |
| 2004 | -3 | 50% |
| 2005 | -1 | -100% |
| 2006 | 0 | 0% |
| 2007 | 0 | 0% |
| 2008 | 0 | 0% |
| 2009 | 0 | 0% |
| 2010 | 2 | 100% |
| 2011 | 0 | 0% |
| 2012 | -1 | 0% |
| 2013 | -1 | 100% |
| 2014 | -1 | 0% |
| 2015 | -1 | 100% |
| 2016 | -4 | 66.67% |
| 2017 | -1 | 0% |
| 2018 | 0 | 0% |
| 2019 | 0 | 0% |
| 2020 | 5 | 100% |
| 2021 | 0 | 0% |
| 2022 | 1 | 0% |
| 2023 | 1 | 0% |
| 2023 | 1 | 0% |
| 2024 | 2 | 100% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 1998 | -14.500.000 | |
| 1999 | -35.884.000 | 59.59% |
| 2000 | -16.656.000 | -115.44% |
| 2001 | -40.877.000 | 59.25% |
| 2002 | -58.456.000 | 30.07% |
| 2003 | -80.773.000 | 27.63% |
| 2004 | -89.216.000 | 9.46% |
| 2005 | -65.637.000 | -35.92% |
| 2006 | -74.673.000 | 12.1% |
| 2007 | -56.908.000 | -31.22% |
| 2008 | -65.543.000 | 13.17% |
| 2009 | -2.069.000 | -3067.86% |
| 2010 | -30.715.000 | 93.26% |
| 2011 | -135.466.000 | 77.33% |
| 2012 | -26.962.000 | -402.43% |
| 2013 | -124.758.000 | 78.39% |
| 2014 | -192.373.000 | 35.15% |
| 2015 | -449.342.000 | 57.19% |
| 2016 | -376.217.000 | -19.44% |
| 2017 | -207.976.000 | -80.89% |
| 2018 | -124.412.000 | -67.17% |
| 2019 | -115.144.000 | -8.05% |
| 2020 | -52.154.000 | -120.78% |
| 2021 | 185.311.000 | 128.14% |
| 2022 | 44.362.000 | -317.72% |
| 2023 | 51.648.000 | 14.11% |
| 2023 | 112.227.000 | 53.98% |
| 2024 | 96.923.000 | -15.79% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 1998 | -8.100.000 | |
| 1999 | -12.940.000 | 37.4% |
| 2000 | -12.896.000 | -0.34% |
| 2001 | -23.065.000 | 44.09% |
| 2002 | -53.595.000 | 56.96% |
| 2003 | -74.798.000 | 28.35% |
| 2004 | -65.141.000 | -14.82% |
| 2005 | -62.680.000 | -3.93% |
| 2006 | -50.090.000 | -25.13% |
| 2007 | -34.495.000 | -45.21% |
| 2008 | -9.175.000 | -275.97% |
| 2009 | 87.732.000 | 110.46% |
| 2010 | 18.746.000 | -368% |
| 2011 | 18.753.000 | 0.04% |
| 2012 | 17.609.000 | -6.5% |
| 2013 | -59.634.000 | 129.53% |
| 2014 | -73.539.000 | 18.91% |
| 2015 | -221.689.000 | 66.83% |
| 2016 | -227.837.000 | 2.7% |
| 2017 | -8.757.000 | -2501.77% |
| 2018 | 20.208.000 | 143.33% |
| 2019 | 48.262.000 | 58.13% |
| 2020 | 85.365.000 | 43.46% |
| 2021 | 304.536.000 | 71.97% |
| 2022 | 175.902.000 | -73.13% |
| 2023 | 159.259.000 | -10.45% |
| 2023 | 135.646.000 | -17.41% |
| 2024 | 118.762.000 | -14.22% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 1998 | 6.400.000 | |
| 1999 | 22.944.000 | 72.11% |
| 2000 | 3.760.000 | -510.21% |
| 2001 | 17.812.000 | 78.89% |
| 2002 | 4.861.000 | -266.43% |
| 2003 | 5.975.000 | 18.64% |
| 2004 | 24.075.000 | 75.18% |
| 2005 | 2.957.000 | -714.17% |
| 2006 | 24.583.000 | 87.97% |
| 2007 | 22.413.000 | -9.68% |
| 2008 | 56.368.000 | 60.24% |
| 2009 | 89.801.000 | 37.23% |
| 2010 | 49.461.000 | -81.56% |
| 2011 | 154.219.000 | 67.93% |
| 2012 | 44.571.000 | -246.01% |
| 2013 | 65.124.000 | 31.56% |
| 2014 | 118.834.000 | 45.2% |
| 2015 | 227.653.000 | 47.8% |
| 2016 | 148.380.000 | -53.43% |
| 2017 | 199.219.000 | 25.52% |
| 2018 | 144.620.000 | -37.75% |
| 2019 | 163.406.000 | 11.5% |
| 2020 | 137.519.000 | -18.82% |
| 2021 | 119.225.000 | -15.34% |
| 2022 | 131.540.000 | 9.36% |
| 2023 | 107.611.000 | -22.24% |
| 2023 | 23.419.000 | -359.5% |
| 2024 | 21.839.000 | -7.23% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 1998 | 29.400.000 | |
| 1999 | 98.377.000 | 70.11% |
| 2000 | 69.994.000 | -40.55% |
| 2001 | 159.548.000 | 56.13% |
| 2002 | 98.543.000 | -61.91% |
| 2003 | 117.853.000 | 16.38% |
| 2004 | -67.978.000 | 273.37% |
| 2005 | -77.462.000 | 12.24% |
| 2006 | 117.802.000 | 165.76% |
| 2007 | 187.726.000 | 37.25% |
| 2008 | 276.675.000 | 32.15% |
| 2009 | 322.185.000 | 14.13% |
| 2010 | 717.257.000 | 55.08% |
| 2011 | 773.048.000 | 7.22% |
| 2012 | 1.015.763.000 | 23.89% |
| 2013 | 1.341.041.000 | 24.26% |
| 2014 | 1.527.894.000 | 12.23% |
| 2015 | 2.400.847.000 | 36.36% |
| 2016 | 2.766.275.000 | 13.21% |
| 2017 | 2.808.663.000 | 1.51% |
| 2018 | 2.967.940.000 | 5.37% |
| 2019 | 3.122.381.000 | 4.95% |
| 2020 | 4.106.002.000 | 23.96% |
| 2021 | 4.270.740.000 | 3.86% |
| 2022 | 4.603.156.000 | 7.22% |
| 2023 | 4.896.897.000 | 6% |
| 2023 | 4.951.549.000 | 1.1% |
| 2024 | 5.286.299.000 | 6.33% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 1998 | 31.500.000 | |
| 1999 | 103.549.000 | 69.58% |
| 2000 | 76.933.000 | -34.6% |
| 2001 | 171.811.000 | 55.22% |
| 2002 | 110.616.000 | -55.32% |
| 2003 | 256.340.000 | 56.85% |
| 2004 | 232.966.000 | -10.03% |
| 2005 | 195.303.000 | -19.28% |
| 2006 | 463.436.000 | 57.86% |
| 2007 | 815.279.000 | 43.16% |
| 2008 | 906.695.000 | 10.08% |
| 2009 | 917.163.000 | 1.14% |
| 2010 | 1.262.623.000 | 27.36% |
| 2011 | 1.303.681.000 | 3.15% |
| 2012 | 1.601.643.000 | 18.6% |
| 2013 | 2.249.217.000 | 28.79% |
| 2014 | 2.490.453.000 | 9.69% |
| 2015 | 3.729.368.000 | 33.22% |
| 2016 | 4.023.690.000 | 7.31% |
| 2017 | 4.633.125.000 | 13.15% |
| 2018 | 4.427.128.000 | -4.65% |
| 2019 | 4.690.039.000 | 5.61% |
| 2020 | 5.848.020.000 | 19.8% |
| 2021 | 6.003.325.000 | 2.59% |
| 2022 | 6.375.074.000 | 5.83% |
| 2023 | 6.758.163.000 | 5.67% |
| 2023 | 6.841.603.000 | 1.22% |
| 2024 | 7.067.121.000 | 3.19% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 1998 | 2.100.000 | |
| 1999 | 5.172.000 | 59.4% |
| 2000 | 6.939.000 | 25.46% |
| 2001 | 12.263.000 | 43.42% |
| 2002 | 12.073.000 | -1.57% |
| 2003 | 138.487.000 | 91.28% |
| 2004 | 300.944.000 | 53.98% |
| 2005 | 272.765.000 | -10.33% |
| 2006 | 345.634.000 | 21.08% |
| 2007 | 627.553.000 | 44.92% |
| 2008 | 630.020.000 | 0.39% |
| 2009 | 594.978.000 | -5.89% |
| 2010 | 545.366.000 | -9.1% |
| 2011 | 530.633.000 | -2.78% |
| 2012 | 585.880.000 | 9.43% |
| 2013 | 908.176.000 | 35.49% |
| 2014 | 962.559.000 | 5.65% |
| 2015 | 1.328.521.000 | 27.55% |
| 2016 | 1.257.415.000 | -5.65% |
| 2017 | 1.824.462.000 | 31.08% |
| 2018 | 1.459.188.000 | -25.03% |
| 2019 | 1.567.658.000 | 6.92% |
| 2020 | 1.742.018.000 | 10.01% |
| 2021 | 1.732.585.000 | -0.54% |
| 2022 | 1.771.918.000 | 2.22% |
| 2023 | 1.861.266.000 | 4.8% |
| 2023 | 1.890.054.000 | 1.52% |
| 2024 | 1.780.822.000 | -6.13% |
BioMarin Pharmaceutical Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 13.62
- Net Income per Share
- 1.35
- Price to Earning Ratio
- 50.89x
- Price To Sales Ratio
- 5.05x
- POCF Ratio
- 39.71
- PFCF Ratio
- 61.45
- Price to Book Ratio
- 2.47
- EV to Sales
- 5.1
- EV Over EBITDA
- 40.17
- EV to Operating CashFlow
- 40.15
- EV to FreeCashFlow
- 62.05
- Earnings Yield
- 0.02
- FreeCashFlow Yield
- 0.02
- Market Cap
- 13,08 Bil.
- Enterprise Value
- 13,20 Bil.
- Graham Number
- 29.06
- Graham NetNet
- 2.91
Income Statement Metrics
- Net Income per Share
- 1.35
- Income Quality
- 1.28
- ROE
- 0.05
- Return On Assets
- 0.04
- Return On Capital Employed
- 0.04
- Net Income per EBT
- 0.86
- EBT Per Ebit
- 1.34
- Ebit per Revenue
- 0.09
- Effective Tax Rate
- 0.14
Margins
- Sales, General, & Administrative to Revenue
- 0.15
- Research & Developement to Revenue
- 0.3
- Stock Based Compensation to Revenue
- 0.08
- Gross Profit Margin
- 0.78
- Operating Profit Margin
- 0.09
- Pretax Profit Margin
- 0.12
- Net Profit Margin
- 0.1
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- 1.73
- Free CashFlow per Share
- 1.12
- Capex to Operating CashFlow
- 0.35
- Capex to Revenue
- 0.04
- Capex to Depreciation
- 1.09
- Return on Invested Capital
- 0.03
- Return on Tangible Assets
- 0.04
- Days Sales Outstanding
- 97.43
- Days Payables Outstanding
- 167.74
- Days of Inventory on Hand
- 771.27
- Receivables Turnover
- 3.75
- Payables Turnover
- 2.18
- Inventory Turnover
- 0.47
- Capex per Share
- 0.61
Balance Sheet
- Cash per Share
- 6,44
- Book Value per Share
- 27,81
- Tangible Book Value per Share
- 25.38
- Shareholders Equity per Share
- 27.81
- Interest Debt per Share
- 5.87
- Debt to Equity
- 0.21
- Debt to Assets
- 0.16
- Net Debt to EBITDA
- 0.39
- Current Ratio
- 3.05
- Tangible Asset Value
- 4,82 Bil.
- Net Current Asset Value
- 1,48 Bil.
- Invested Capital
- 3706922999
- Working Capital
- 2,19 Bil.
- Intangibles to Total Assets
- 0.07
- Average Receivables
- 0,66 Bil.
- Average Payables
- 0,43 Bil.
- Average Inventory
- 1160801500
- Debt to Market Cap
- 0.08
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
BioMarin Pharmaceutical Inc. Profile
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
- CEO
- Mr. Alexander Hardy
- Employee
- 3.401
- Address
-
770 Lindaro Street
San Rafael, 94901
BioMarin Pharmaceutical Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Ms. Humaira Serajuddin Senior Vice President & Chief Marketing Officer |
70 |
| 2 |
Ms. Amy Wireman Executive Vice President & Chief People Officer |
70 |
| 3 |
Dr. C. Greg Guyer Ph.D. Executive Vice President & Chief Technology Officer |
70 |
| 4 |
Mr. Brian R. Mueller Chief Financial Officer & Executive Vice President |
70 |
| 5 |
Traci McCarty Group Vice President of Investor Relations |
70 |
| 6 |
Ms. Erin Burkhart Group Vice President & Chief Accounting Officer |
70 |
| 7 |
Dr. Kevin Eggan Ph.D. Chief Scientific Officer & Senior Vice President of Research and Early Development |
70 |
| 8 |
Mr. Alexander Hardy President, Chief Executive Officer & Director |
70 |
| 9 |
Mr. George Eric Davis Executive Vice President, Chief Legal Officer, General Counsel & Secretary |
70 |
BioMarin Pharmaceutical Inc. Competitors
